Premium
Bcl‐2 expression in mycosis fungoides before and after PUVA therapy
Author(s) -
Weshahy Hani,
Mahgoub Doa,
ElEishy Nermine,
ElTawdy Amira Mohamed,
Bassiouny Dalia Ahmed,
Hunter Nahla,
Hindawi Ali
Publication year - 2010
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/j.1600-0781.2010.00496.x
Subject(s) - mycosis fungoides , puva therapy , dermatology , medicine , immunohistochemistry , stage (stratigraphy) , staining , significant difference , pathology , lymphoma , psoriasis , biology , paleontology
PUVA is the first therapeutic choice in early stages of mycosis fungoides (MF). In this study the effect of PUVA on bcl‐2 expression in MF was assessed in 15 patients (three stage Ia and 12 stage Ib) and 10 controls. Two biopsies were taken from each patient before and after 24 sessions of PUVA therapy. Histopathological assessment and immunohistochemical staining for bcl‐2 was performed and showed positive bcl‐2 staining of lymphocytes in 53% of MF cases (8/15) before PUVA, with no statistically significant difference in the bcl‐2 level before and after PUVA therapy ( P value 0.3). A statistically significant difference was found in the bcl‐2 level between control samples and MF patients' biopsies before ( P value 0.02) and after PUVA therapy ( P value 0.011). In conclusion, a lack of decline in the bcl‐2 level and the absence of clinical or histopathological correlation with the bcl‐2 level before and after PUVA therapy in MF patients suggest that PUVA‐induced apoptosis in MF cases may occur through pathways other than bcl‐2 inhibition.